Jiangxi Jinko Issues Preliminary 9-month Estimates As Part Of IPO Process

Jinko Solar Co. Ltd. or Jiangxi Jinko, the principal operating subsidiary of JinkoSolar Holding Co., Ltd. (JKS), is estimated to report net income attributable to the shareholders of Jiangxi Jinko of between RMB 625 million and RMB 655 million for the nine months ending September 30, 2021. Excluding extraordinary gains and losses, estimated net income attributable to the shareholders of Jiangxi Jinko is expected to be between RMB 230 million and RMB 260 million. The projected revenues of Jiangxi Jinko under PRC GAAP are expected to be between RMB 23.6 billion and RMB 23.8 billion.

Jiangxi Jinko disclosed the estimates in accordance with PRC GAAP as part of its IPO process. JinkoSolar owns approximately 73.28% equity interest in Jiangxi Jinko.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT